BioSpace News Archive

InDex Pharmaceuticals Holding AB announced that the company will be exhibiting at the United European Gastroenterology Week October 8-11, 2022 in Vienna.

Allecra Therapeutics announced that the final results from its Phase 3 ALLIUM trial investigating the combination of cefepime/enmetazobactam in patients with complicated urinary tract infections have been published in the Journal of the American Medical Association.

Enzolytics, Inc. announces the completion of the first phase of the animal toxicology studies on its ITV-1 anti-HIV therapeutic.

Hoffmann-La Roche Limited announced that the Canadian Agency for Drugs and Technologies in Health pan-Canadian Oncology Drug Review Expert Review Committee has issued two final recommendations for TECENTRIQ®.

KalVista Pharmaceuticals, Inc., announced that the compensation committee of KalVista’s board of directors granted four newly-hired employees inducement options to purchase an aggregate of 18,000 shares of KalVista common stock on October 3, 2022 as inducements material to each employee entering into employment with KalVista.

, Arch Biopartners Inc., a clinical stage company focused on the development of innovative technologies and novel therapeutics targeting organ inflammation, welcomed Mr. Farris Smith of Novo Nordisk Canada Inc as a Strategic Advisor for general corporate activity and business development of the Company’s drug candidates.

Nevro Corp. announced that the company will report its financial results for the third quarter ended September 30, 2022 after the market closes on November 2, 2022.

LEXEO Therapeutics, Inc. announced new clinical data from its ongoing study of LX1001 for APOE4-associated Alzheimer’s disease will be presented at the 29th European Society of Gene and Cell Therapy Annual Meeting, which is being held live in Edinburgh, Scotland and virtually from October 11-14, 2022.

Areteia Therapeutics announces two key leadership appointments: Dr. Eric Bradford M.D. as Chief Medical Officer and Robin Walker J.D. as Chief Legal Officer and Corporate Secretary.

HAPPE Spine announces the addition of two more issued patents in a growing portfolio establishing HAPPE as the leader of next generation orthopaedic and spinal implants enabled by the HAPPE™ platform.